Venture Visionary Partners LLC Decreases Holdings in Eli Lilly and Company $LLY

Venture Visionary Partners LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 18.3% during the 1st quarter, HoldingsChannel reports. The fund owned 10,334 shares of the company’s stock after selling 2,308 shares during the quarter. Venture Visionary Partners LLC’s holdings in Eli Lilly and Company were worth $8,536,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in LLY. Redwood Investments LLC increased its stake in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company’s stock worth $1,705,000 after buying an additional 12 shares during the period. Hobbs Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock worth $1,205,000 after buying an additional 12 shares during the period. Hixon Zuercher LLC increased its stake in shares of Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock worth $1,477,000 after buying an additional 12 shares during the period. O Brien Wealth Partners LLC increased its position in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after purchasing an additional 12 shares during the period. Finally, Ascent Capital Management LLC increased its position in Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock valued at $409,000 after purchasing an additional 12 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 0.3%

Eli Lilly and Company stock opened at $698.89 on Tuesday. The company has a market capitalization of $661.47 billion, a price-to-earnings ratio of 45.68, a price-to-earnings-growth ratio of 0.98 and a beta of 0.44. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $972.53. The stock has a 50-day moving average price of $763.06 and a 200 day moving average price of $793.64. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The business’s revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the business earned $3.92 earnings per share. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.9%. Eli Lilly and Company’s payout ratio is 39.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jamere Jackson acquired 200 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders bought 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is owned by insiders.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. HSBC cut shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and dropped their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $950.17.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.